Zybio

In Vitro Diagnosticszybio.com

Zybio is a privately held Chinese in vitro diagnostics (IVD) company that develops, manufactures, and globally distributes diagnostic instruments and reagents across nine product lines, serving hospital laboratories, primary care clinics, veterinary facilities, and academic research institutions through a distributor-led go-to-market model.

Company typePrivate
Founded2008
HeadquartersDadukou, China
Headcount1,001–5,000
GTM typeB2B
OfferingHardware or Manufacturing

Zybio firmographics

Firmographics

Name: Zybio
Legal name: Zybio Inc.
Website: https://zybio.com
Company type: Private
Founded year: 2008
Operating status: Operating
Headcount range: 1,001–5,000 employees
Short description: Zybio is a privately held Chinese in vitro diagnostics (IVD) company that develops, manufactures, and globally distributes diagnostic instruments and reagents across nine product lines, serving hospital laboratories, primary care clinics, veterinary facilities, and academic research institutions through a distributor-led go-to-market model.
Ownership category
akta.pro rank

Zybio industry classification

Industry

Product category: In Vitro Diagnostics
NAICS: In-Vitro Diagnostic Substance Manufacturing (325413), Medical Equipment and Supplies Manufacturing (3391), Analytical Laboratory Instrument Manufacturing (334516)
SIC: In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry: IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)
akta.pro secondary industries: Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN)

Keywords

In vitro diagnostics
Clinical chemistry analyzers
Molecular diagnostic equipment
Hematology analyzers
Chemiluminescence immunoassay

Where Zybio is headquartered

Location

Headquarters

HQ city: Dadukou
HQ country: China
HQ region: Asia

Offices11 records

Markets served

Zybio business model

Business model

GTM type: B2B
Offering type: Hardware or Manufacturing
Cost components: Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

IVD Instruments and Analyzers: Sale of automated diagnostic instruments including MALDI-TOF MS systems, hematology analyzers, chemistry analyzers, chemiluminescence immunoassay analyzers, coagulation analyzers, urinalysis systems, and molecular diagnostics instruments. Instruments are sold to healthcare facilities with ongoing reagent and consumable revenue.
IVD Reagents and Consumables: Proprietary reagents for all instrument platforms including chemistry reagents (100+ items), hematology reagents, coagulation reagents, chemiluminescence reagents, molecular detection kits, and microbiology reagents. Consumables include sample collection tubes, extraction kits, and test strips.
Technical Services and Support: Installation, training, and after-sales technical support services. Warranty services (12-month warranty for instruments) with response time commitments and service engineer deployment to customer countries.

Go-to-market motion3 records

Distribution channels7 records

Marketing channels9 records

Zybio product offering

Product offering

Core offering

Zybio develops, manufactures, sells, and provides technical services for in vitro diagnostic (IVD) equipment and proprietary reagents across nine product lines: Microbiology (MALDI-TOF MS), Molecular (nucleic acid extraction and PCR), Clinical Chemistry, Chemiluminescence Immunoassay (CLIA), Hematology, Hemostasis/Coagulation, Urinalysis, Point-of-Care Testing (POCT), and Laboratory Automation. The company sells IVD analyzers to hospitals, laboratories, and clinics alongside a recurring consumables business (reagents, kits, sample tubes).

Product overview

Zybio is an in vitro diagnostics (IVD) company offering a comprehensive portfolio of diagnostic products across 9 product lines: Microbiology (MALDI-TOF MS systems including EXS 2600 and EXS 3000), Molecular (nucleic acid extraction systems EXM 3000/6000, PCR systems EXP 160/960/160R, ZIP-96V), Clinical Chemistry (EXC 200/400/460/2000 analyzers with 100+ reagents), Chemiluminescence (EXI 1800/2400/1820/8000), POCT (Q8 Pro, EXR110/120, MxA, SARS-CoV-2 kits, Q7), Hemostasis (EXT 3800/4800/9800 with MOCAP technology, YX-2000/3000), Hematology (Z3/Z50/EXZ 6000/8000 series), Urinalysis (U3600/1600/2610), and Veterinary (Z4/Z52 VET, EXM/EXP veterinary systems). The company also offers laboratory automation through EXLAB and teaching equipment via EXS 800. Products range from small desktop analyzers for primary care to high-throughput systems for central laboratories, supported by a comprehensive reagent portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

EXS 2600 MALDI-TOF MS System Rapid microorganism identification system using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Tests 96 spots on one plate with target-in/out time under 1 minute; rich database covering bacteria, filamentous fungi, yeasts, mycobacteria. Targets clinical microbiology laboratories.
EXS 3000 MALDI-TOF MS System High-throughput MALDI-TOF mass spectrometry system for accurate microbial identification with comprehensive 5,000+ species strain database and advanced sample pretreatment kits. Targets high-volume clinical microbiology labs.
EXM 3000 Automatic Nucleic Acid Isolation System

Quantifiable outcome

94%+ species-level identification accuracy for blood culture enrichment using MALDI-TOF MS
+8 more outcomes

Companies that use Zybio

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Zybio technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature9 records

Zybio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

Beckman Coulter Commercial Enterprise (China) Co., Ltd.coreStrategic or Co-development Partner · 31 October 2025Strategic cooperation agreement signed on October 31, 2025 at NCLM exhibition in China. Both parties will integrate technological expertise and innovation advantages to drive deep integration of medical diagnostic technologies. The partnership aims to bring new vitality to China's laboratory medicine under the 'Healthy China' strategy, with Mr. Wenhao Sun representing Zybio and Mr. Huai Chen (Global Vice President of Beckman Coulter Diagnostics) representing Beckman Coulter.

Scale indicators8 records

Recent moves11 records

Expansion highlights6 records

Zybio competitors and assessment

Company assessment

Direct peers

Autobio Diagnostics: Zhengzhou-headquartered Chinese IVD company offering immunoassay (CLIA), microbiology, clinical chemistry, and molecular diagnostics for hospital and clinical lab markets. Direct Chinese competitor with overlapping product lines and customer base.
Mindray: Shenzhen-headquartered Chinese medical device and IVD leader with comprehensive portfolio across patient monitoring, in-vitro diagnostics, and medical imaging. Closest direct comparable to Zybio in scale, product breadth, and global distribution ambition, though Mindray is significantly larger and publicly listed.
Snibe (Shenzhen New Industries Biomedical Engineering): Shenzhen-based Chinese IVD leader specializing in chemiluminescence immunoassay (CLIA) analyzers and reagents, with growing chemistry and infectious disease menu. Direct competitor to Zybio's EXI series in immunoassay diagnostics.
bioMérieux: French IVD specialist with leading global position in microbiology (VITEK MS MALDI-TOF system is the dominant competitor to Zybio's EXS series) and industrial microbiology. Directly comparable in MALDI-TOF-based microbial ID and broader microbiology diagnostics.
Maccura Biotechnology: Chengdu-based Chinese IVD company with broad portfolio in clinical chemistry, immunoassay, hematology, coagulation, and molecular diagnostics. Comparable mid-tier Chinese IVD peer serving similar hospital and primary care segments.
Bruker Corporation: US-headquartered scientific instrument maker with the MALDI Biotyper, the global market-leading MALDI-TOF MS platform for clinical microbial identification. Direct technology and product competitor to Zybio's MALDI-TOF EXS 2600/3000 systems.

Broad incumbents

Siemens Healthineers: Germany-headquartered global medical technology company with a sizable IVD franchise (Atellica, ADVIA Centaur, Dimension systems) spanning immunoassay, chemistry, hematology, and lab automation. Broad incumbent competitor in hospital IVD.
Roche Diagnostics: Division of Roche Holding and the global #1 IVD player, offering cobas chemistry/immunoassay systems, molecular diagnostics, and lab automation. Dominant incumbent competing across nearly every Zybio product line at tier-1 hospitals worldwide.
Beckman Coulter Diagnostics: Danaher-owned global IVD and life science research company offering comprehensive chemistry, immunoassay, hematology, and lab automation solutions. Recent Zybio strategic partner and direct competitor across multiple modalities, with much larger global installed base.
Abbott Diagnostics: US-headquartered global diagnostics franchise (ARCHITECT, Alinity, CELL-DYN) covering immunoassay, clinical chemistry, hematology, molecular, and point-of-care testing. Broad incumbent competing against Zybio in both mature and emerging hospital markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Zybio compliance and trust

Trust signal

Compliance3 records

Zybio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Zybio leadership team

Management profile

Number of profiles

Profiles8 records

Zybio subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Zybio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Zybio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zybio

What does Zybio do?

Is Zybio a public or private company?

Zybio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Zybio founded?

Zybio was founded in 2008. It employs 1,001 to 5,000 people.

Where is Zybio based?

Zybio is headquartered in Dadukou, China, in the Asia region.

How does Zybio make money?

Three revenue lines are on record. IVD Instruments and Analyzers are the primary driver. The others are IVD Reagents and Consumables and technical Services and Support.

Who are Zybio's main competitors?

Direct peers on record are Autobio Diagnostics, Mindray, Snibe (Shenzhen New Industries Biomedical Engineering), bioMérieux, Maccura Biotechnology and Bruker Corporation. Broad incumbents are Siemens Healthineers, Roche Diagnostics, Beckman Coulter Diagnostics and Abbott Diagnostics.

Does Zybio have an API?

No public API is recorded for Zybio.

What industry is Zybio in?

Zybio's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST). Its NAICS code is 325413 and its SIC code is 2835.